Betta IPO Tells Tale Of Shifting Strategy By China Innovators
This article was originally published in PharmAsia News
As a national innovation darling, Betta Pharma is gearing up to a much-hyped public listing in China. Combing through its 300-plus page prospectus, however, unveils a different Betta striving to diversify amid looming competition and price pressure.
You may also be interested in...
The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.
Podcast: Living In China's Coronavirus Lockdown; Novartis and England's 'Public Health' Alliance; Biogen's Moment of Truth Approaches
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.